Investor Overview

OTCQB:NNMX

nanōmix

Leader in mobile point-of-care diagnostics

October 2022

Safe Harbor Statement

Statements contained in this presentation that are not historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the intent, belief or current expectations of Nanomix and its management with respect to such things as: investment objectives and the Company's ability to make investments in a timely manner on acceptable terms; references to future success of the Company's products; the Company's business strategy; estimated future capital expenditures; sales of the Company's products; competitive strengths and goals; and other similar matters.

Such statements, which are only expectations, reflect management's current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events or performance may differ materially from the forward-looking statements due to a number of important factors including, but not limited to: ability to develop, commercialize and market new products; ability to manufacture products; ability to obtain necessary regulatory approvals; market acceptance of our products; ability to fund research and development; ability to sell products internationally; loss or impairment of sources of capital; ability to attract and retain qualified personnel; the highly competitive market which includes a number of competing companies with strong relationships with customers and with significantly greater financial and other resources that are available to Nanomix.

Nanomix undertakes no obligation to publicly update forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Nanomix expectations with regard to the forward-looking statements or the occurrence of unanticipated events.

Nanomix Delivers On the Promise of Point of Care Testing

A >$40B[1] Market Ripe for Disruption

1. Leader in decentralized POC testing – time critical information to improve patient outcomes
   - Rapidly growing market for pre-hospital evaluations and telemedicine
2. The only distributed test for screening critical infections, including sepsis, a huge unmet need
   - CE approved - rapidly expanding sales channels in Europe, Asia and Middle East
   - Drives unique rapid testing solutions for sepsis / pneumonia
   - Will save lives, save costs, and reduce the inappropriate use of antibiotics
3. Most Advanced Mobile Diagnostic Platform
   - Broadly expandable to include many different tests and new products
4. Deep Technical Expertise and IP
   - All technology developed and wholly owned by Nanomix
   - 21 issued and 2 pending patents
5. High margin, recurring consumables business model

OTCQB:NNMX

nanomix

1. Fortune Business Insights, Market Research Report, 2022

Nanomix eLab

A Complete Mobile Immunodiagnostic System

ACCURATE	Proprietary sensor technology brings immunoassay sensitivity and specificity to the POC
FAST	Microfluidics technology delivers reproducibility and a quick 10 – 15 minutes sample-to-answer
MOBILE	Rugged design and menu driven software enables use in mobile settings with limited training
CONNECTED	Store data, send HL7 or simple text data via Bluetooth, or display results in QR format

Initial Nanomix strategy: target assays where *high accuracy* and *immediacy* are of great value in *patient care*.

Critical Infections

A Global Health Challenge

+++

1 in 4 acquire sepsis in the hospital[2]

of all deaths globally are caused by sepsis[1]

$$$

$32,000

Cost per sepsis patient[4]

Pneumonia patients Re-hospitalized >30 days[3]

190 million

Sepsis & pneumonia cases annually

nanōmix

1. Rudd, et al. Lancet. 2020; 395: 200-11
2.Markwart, et al. Intensive Care Med. 2020; 46(8): 1536-51

3. Prescott, H. C., Sjoding, M. W. & Iwashyna, T. J. Diagnoses of early and late readmissions *Ann. Am. Thorac. Soc.* **11**, 1091–1100 (2014).
4. Heublein, et al. J Infect. 2017; 74(2): 107-17

The Problem

PCT and other host response biomarkers are oftentimes not utilized during the initial patient evaluation due to slow time to results

- Current solutions are lab-based (e.g. Vidas, Kryptor, etc.) and the slow turn-around time (> 1hr) results in caregivers making treatment decisions before the diagnostics are available. Quality outcomes rely heavily on provider experience and are difficult to protocolize.

It is estimated that 75% of Sepsis, Pneumonia and other critical infections are community acquired infections making timely diagnosis and care decisions difficult

- Current solutions may delay assessing patients with community acquired infections. To improve patient outcomes, caregivers require diagnostic evidence and clinical collaboration to make transition of care and antibiotic decisions.

nanōmix

Nanomix eLab – The Solution

A Complete Mobile Immunoassay Diagnostic System

TIME

11-minute sample to answer diagnostic cuts hours off information delivery and improves outcome for the patient

Host response biomarkers in first minutes for informed care decisions

ACCURACY

Lab quality information (sensitivity, specificity) proven in multi-site clinical trials

The quality of critical POC diagnostics supports biomarker-guided therapy

MOBILITY

Testing at patient side in or outside hospital or on the way to the hospital

Rapid POC diagnostic testing speeds care decisions and reduces unnecessary hospital transfers

S1 Assay Panel

Uniquely Positioned to Significantly Impact Sepsis Treatment and Patient Outcomes

Sepsis by the Numbers

$2.5B Worldwide TAM[4]

Huge Global Health Challenge

of all deaths are due to sepsis[1]

~50 million

annual incidence[1]

Test accessibility and rapid results are critical



increase in mortality for every hour treatment is delayed[3]



of cases are community based[2]

nanōmix

1. Rudd, et al. Lancet. 2020; 395: 200-11
2. Markwart, et al. Intensive Care Med. 2020; 46(8): 1536-51
3. Radius Global Market Research. Sept 2019, report for Sepsis Alliance
4. Nanomix estimate based on incidence factored by IVD test price

Sepsis ED Pathway: Traditional Central Lab vs Nanomix eLab



1. Hua Yu, et al. Combining procalcitonin with the qSOFA and sepsis mortality prediction, Medicine (Baltimore) 2019 Jun; 98(23): e15981. Published online 2019 Jun 7

nanōmix

OTCQB:NNMX

Competitive Overview

eLab and S1 – anecdotal systems

nanōmix eLab	Nexus Dx	PATHFAST™ PCT	LUMIRAdx	AQT90 FLEX	VIDAS®	Kryptor	i-STAT	Idylla (SeptiCyte)
Multiplex Sepsis markers: PCT, CRP, LAC	PCT	PCT	CRP	PCT CRP	PCT	PCT	LAC	Genetic markers
Mobile, Handheld Analyzer	Benchtop	Benchtop	Benchtop	Benchtop	Benchtop	Benchtop	Mobile (limited)	Benchtop
Solid state sensors - No onsite calibration - No user maintenance, replaceable parts	Optical	Optical	Optical	Optical	Optical	Optical	X	RT=PCR for genetic markers (host response)
11 minutes to result	20 min	17 min	4 min	21 min	20 min	~20 min	~ 2 min	1 hour
Whole Blood sample option for all tests	Yes (PCT)	Yes (PCT)	Yes (CRP)	Yes (PCT, CRP)	No	No	Yes	Whole blood
Immediate use Cassette from fridge or room temp (no waiting)	No - Warm at least 15 min prior to use	Yes	Yes		Yes	Yes	Warm to room temp if refrigerated	Room temperature
Measuring Range ~ to core lab for each test	No .3 – 10 ug/L	Similar	Similar	Similar	Yes	Yes	Similar	N/A

Unique Mobile POC Solution

Differentiated

- **Only** POC multiplexed panel for PCT, CRP, & LAC
- Results in 11 minutes
- Lab quality results

Credible

- **Proven** in Multi-center clinical trials
- Consistent with current clinical information
- CE Marked

Customer Ready

- **Critical** results in 11 minutes transforms standards of care
- **Customer evaluations underway** in Europe

Global Commercial Launch

Local market analysis/ distributor identification → Establish Partnerships → KOL and customer evaluations → Customer and Menu Expansion

Distributors:
- Signed
- Negotiating
- Discovery

Evaluations/Studies:
- Underway
- Pending

nanōmix

Power of the eLab Platform

Highly Scalable Platform for Multiple Applications

Test expansion creates a very large TAM[1]



1. Test expansion requires normal development and regulatory approval for any IVD product

The Nanomix system is based on proprietary, innovative technology providing significant advantages in accuracy, portability and cost

Nano-Electric Sensors with Electro-Chemical Detection



- Advantages over traditional optical techniques
- Multiplex and multiple assay techniques
- Inexpensive, sensitive sensors

Precision Sample Preparation in a **Microfluidic Cartridge**



- Precision movement of fluids via programmatic control of assay protocols
- Enables reproducibility on a portable instrument

Easy to use **Portable Analyzer**

- Designed for use in or outside of traditional laboratory environments
- Menu driven screens for intuitive use
- Minimal training for non-professionals

Technology developed and wholly owned by Nanomix including 21 issued and 2 pending patents

Decentralized Diagnostic Testing Venues

Testing at POC improves decision making, improves patient outcomes, and will lower costs

The Institute of Medicine (IOM) estimates that **$750 billion**—30% of the U.S. annual health care budget—is **wasted** on unnecessary services and inefficient delivery

…up to **34%** of Medicare patients transported by EMS to an ED **could have been safely treated in an alternative setting**[1]



nanōmix

1. Mobile Integrated Healthcare Practice: A Healthcare Delivery Strategy to Improve Access, Outcomes, and Value

Business Model

Revenue and margin driven by consumable cartridge sales

ELAB ANALYZER

- Analyzer runs multiple cartridge types

CARTRIDGES

- Primary Source of Revenue
- À la carte pricing based on specific tests
- Single use

Purchase, rental and subscription programs available

Test price depends on assay content. Overall GM target 65%

High margin, recurring consumables business model

Target Milestones

Near-term catalysts to drive shareholder value

Management

Experienced Management Team

Dr. Thomas Schlumpberger, CEO

Thomas is an experienced executive with more than 20 years working in the life sciences industry and is a recognized expert in point of care applications. Most recently he was CEO of Pictor Ltd, a biotechnology company focused on diagnosing complex diseases from a single small blood sample. With his background in business development, Dr. Schlumpberger has closed over 70 collaboration, distribution, and licensing deals totaling more than $1.5 billion in value. Thomas received a PhD in Molecular and Cell Biology from the University of California at Berkeley with distinction and a Masters in Electrical Engineering and Information Theory from the Technical University Munich.

John Hardesky, Chief Commercial Officer

John is an accomplished leader with over 20 years of commercialization experience in the clinical diagnostics market. John has built a strong track record of innovative concept to execution strategies that yield turnaround and growth results. While holding leadership positions in manufacturer and distribution, start-up through large companies, he launched over 20 different product platforms and value-based solutions to market. John is passionate about creating a culture of entrepreneurial spirited drive with execution confidence.

Vidur Sahney, Chief Operating Officer

Vidur brings more than 23 years of experience in operations, quality, validation, manufacturing, and research. His experience includes FDA Class III and CE product approvals and commercialization activities. He has set up and scaled production, technical operations, and supply chains in several companies, including ExThera Medical, JUUL Labs, Thoratec, and Loma Vista Medical. He is a graduate of San Francisco State University and was trained in Six Sigma Lean Manufacturing by Toyota at the NUUMI plant in Fremont, CA.

Sherrill Lavagnino, Vice President of Engineering

Sherrill has over 25 years of experience in developing software and integrated hardware systems. As Senior Director of Engineering at Cognex Corporation, Sherrill was responsible for the successful launch of highly integrated manufacturing and inspection systems. Prior to Cognex she held the position of Senior Software Engineer at Isys Controls. The author of numerous patents, Sherrill graduated from Smith College.

Bradley Johnson, Ph.D.; Senior Director of Technology Development

Brad has more than 10 years of broad experience in biotechnology and biomedical devices. His primary focus is in vitro diagnostic methods, related instrumentation and technology including microfluidics and electro chemical biosensors. He has been instrumental in the development of technology underpinning the Nanomix platform and in advanced approaches to automated production systems. He received his Ph.D. in Bioengineering from University of California, Berkeley.

Key Statistics

Ticker	Exchange	Share Price
		(9/23/2022)
NNMX	**OTCQB**	**$0.40**

Shares Outstanding	Market Cap	Insider Ownership
(9/23/2022)	(9/23/2022)	(9/23/2022)
48.0M	**$19.2M**	**58.4%**

nanōmix

www.nano.com
twitter.com/nanomixinc
linkedin.com/company/nanomix

Investor Relations Contact:
Natalya Rudman
Crescendo Communications, LLC
Email: NNMX@crescendo-ir.com
Tel: (212) 671-1020 Ext. 304

OTCQB:NNMX